GlassScriptPhysician profile
Michael A Musgrove
NPI 1033166368
$19,566.21
in general payments reported to CMS, 2019-2025
40 companies · $4,458 in 2025
The $4,458 reported for 2025 was more than what 94% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,319 · 2020: $1,149 · 2021: $980 · 2022: $2,411 · 2023: $3,407 · 2024: $3,842 · 2025: $4,458.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K · Education: $13.20.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,694.32 |
| Education | $13.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $3,182.87 | 2019-2025 | Rexulti, Nuedexta, Abilify Mycite |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,608.65 | 2021-2025 | Caplyta |
| Neurocrine Biosciences, INC. | $1,603.94 | 2019-2025 | Ingrezza |
| Lundbeck LLC | $1,510.98 | 2019-2025 | Rexulti, Abilify Maintena |
| Alkermes, INC. | $1,060.75 | 2021-2025 | Aristada, Lybalvi, Aristada Initio |
| Abbvie INC. | $1,058.89 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $877.49 | 2019-2025 | Trintellix |
| Teva Pharmaceuticals USA, INC. | $876.59 | 2019-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Neuronetics, INC. | $810.82 | 2019-2024 | Neurostar Tms Therapy System |
| Corium, LLC | $784.75 | 2021-2025 | Azstarys |
| Bausch Health US, LLC | $662.98 | 2019-2025 | Aplenzin, Wellbutrin |
| Sunovion Pharmaceuticals INC. | $642.32 | 2019-2022 | |
| Axsome Therapeutics, INC. | $622.95 | 2022-2025 | Auvelity, Sunosi |
| Vanda Pharmaceuticals INC. | $594.21 | 2019-2025 | Fanapt, Hetlioz |
| Janssen Pharmaceuticals, INC | $498.38 | 2019-2025 | Spravato, Invega Sustenna, Invega Trinza |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $490.03 | 2019-2024 | Jornay Pm |
| Allergan, INC. | $360.61 | 2019-2020 | |
| Noven Therapeutics, LLC | $279.04 | 2023-2025 | Xelstrym, Secuado |
| Tris Pharma INC | $264.75 | 2022-2025 | Dyanavel Xr |
| Idorsia Pharmaceuticals US INC | $245.36 | 2022-2025 | Quviviq, Quviviq |
| Supernus Pharmaceuticals, INC. | $210.53 | 2023-2025 | Qelbree, Qelbree |
| Biogen, INC. | $152.41 | 2024-2025 | Zurzuvae |
| Jazz Pharmaceuticals INC. | $141.15 | 2019-2021 | |
| Neos Therapeutics, LP | $135.13 | 2019-2023 | Adzenys Xr-Odt |
| Owp Pharmaceuticals, INC. | $103.99 | 2019-2024 | Subvenite |
| Shire North American Group INC | $103.17 | 2019 | |
| Avanir Pharmaceuticals, INC. | $101.27 | 2019-2022 | |
| Eisai INC. | $82.72 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $72.15 | 2024-2025 | Cobenfy |
| Vertical Pharmaceuticals, LLC | $69.83 | 2019-2024 | Relexxii |
| Adlon Therapeutics L.P. | $65.51 | 2019-2021 | |
| Arbor Pharmaceuticals, INC. | $64.81 | 2019-2022 | |
| Indivior INC. | $54.26 | 2022-2023 | Perseris |
| Collegium Pharmaceutical, INC. | $36.80 | 2025 | Jornay Pm |
| Azurity Pharmaceuticals, INC. | $33.54 | 2022 | |
| Avion Pharmaceuticals | $26.11 | 2023 | Methylphenidate Hydrochloride |
| Harmony Biosciences LLC | $26.04 | 2023 | Wakix |
| Almatica Pharma LLC | $20.53 | 2021 | |
| Aytu Biopharma, INC. | $18.07 | 2021 | |
| Brainsway USA INC | $11.83 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Musgrove listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.